Filing Flows › Spero Therapeutics (SPRO) › R&D spending
Spero Therapeutics (SPRO) R&D spending by quarter
Spero Therapeutics' R&D spending was $2.9M in Q1 2026 (first quarter 2026), -48% from Q4 2025. Over the last 6 quarters it ranged from $2.9M (Q1 2026) to $28.8M (Q4 2024).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q1 2026 | $2.9M | -48% | -79% |
| Q4 2025 | $5.6M | -35% | -81% |
| Q3 2025 | $8.6M | -19% | — |
| Q2 2025 | $10.7M | -22% | — |
| Q1 2025 | $13.6M | -53% | — |
| Q4 2024 | $28.8M | — | — |
Q1 2026 at a glance
Spero Therapeutics, Q1 2026: revenue $258K (-96% year over year), net loss $7.2M, operating cash flow $15.9M. The chart follows the revenue to costs, profit and cash.
Questions
What is Spero Therapeutics' R&D spending?
Spero Therapeutics' R&D spending was $2.9M in Q1 2026 (first quarter 2026), -48% from Q4 2025.
How has Spero Therapeutics' R&D spending changed?
Over the last 6 quarters it ranged from $2.9M (Q1 2026) to $28.8M (Q4 2024).